0001213900-22-069123.txt : 20221104 0001213900-22-069123.hdr.sgml : 20221104 20221103192959 ACCESSION NUMBER: 0001213900-22-069123 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20221020 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221104 DATE AS OF CHANGE: 20221103 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ENZO BIOCHEM INC CENTRAL INDEX KEY: 0000316253 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 132866202 STATE OF INCORPORATION: NY FISCAL YEAR END: 0731 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-09974 FILM NUMBER: 221359786 BUSINESS ADDRESS: STREET 1: 60 EXECUTIVE BLVD CITY: FARMINGDALE STATE: NY ZIP: 11735 BUSINESS PHONE: 5167555500 MAIL ADDRESS: STREET 1: ENZO BIOCHEM INC STREET 2: 60 EXECUTIVE BLVD CITY: FARMINGDALE STATE: NY ZIP: 11735 8-K 1 ea167979-8k_enzobio.htm CURRENT REPORT
0000316253 false 0000316253 2022-10-20 2022-10-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): November 3, 2022 (October 20, 2022)

 

Enzo Biochem, Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

New York

(State or Other Jurisdiction of Incorporation)

 

001-09974   13-2866202
(Commission File Number)   (IRS Employer Identification No.)
     
81 Executive Blvd. Suite 3    
Farmingdale, New York   11735
(Address of Principal Executive Offices)   (Zip Code)

 

(212) 583-0100

(Registrant’s Telephone Number, Including Area Code) 

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol   Name of Each Exchange on Which Registered
Common Stock, $0.01 par value   ENZ   The New York Stock Exchange

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-1 of this chapter). 

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On October 20, 2022, Enzo Biochem, Inc. (the “Company”) entered into (i) a first amended and restated employment agreement with Kara Cannon, its Chief Operating Officer (the “COO A&R Agreement”), and (ii) a second amended and restated employment agreement with Hamid Erfanian, its Chief Executive Officer (the “CEO Second A&R Agreement,” and together with the COO A&R Agreement, the “Employment A&R Agreements”).

 

Pursuant to the amended terms of the Employment A&R Agreements, each of Ms. Cannon and Mr. Erfanian is now eligible to receive a transaction bonus in the event that there is a sale of an operating subsidiary.

 

The foregoing descriptions of the Employment A&R Agreements are not complete and are qualified in their entirety by reference to full text of the COO A&R Agreement and the Employment A&R Agreements, copies of which are attached hereto as Exhibit 10.1 and Exhibit 10.2, respectively, and are incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit
Number
  Description
     
10.1   First Amended and Restated Employment Agreement between Enzo Biochem, Inc. and Kara Cannon, effective as of October 20, 2022
10.2   Second Amended and Restated Employment Agreement between Enzo Biochem, Inc. and Hamid Erfanian, effective as of October 20, 2022
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ENZO BIOCHEM, INC.
     
Date: November 3, 2022  By: /s/ Hamid Erfanian
    Hamid Erfanian
    Chief Executive Officer

 

 

2

 

 

EX-10.1 2 ea167979ex10-1_enzobio.htm FIRST AMENDED AND RESTATED EMPLOYMENT AGREEMENT BETWEEN ENZO BIOCHEM, INC. AND KARA CANNON, EFFECTIVE AS OF OCTOBER 20, 2022

Exhibit 10.1

 

FIRST AMENDED AND RESTATED
EXECUTIVE EMPLOYMENT AGREEMENT

 

This Executive Employment Agreement (the “Agreement”), dated as of March 21, 2022 (the “Effective Date”), as amended October 20, 2022 (the Amendment Date”), made between Enzo Biochem, Inc., a New York corporation, with its principal office at 527 Madison Avenue, New York, New York 10022 (the “Company”) and Kara Cannon (the “Executive”) (collectively, the “Parties”).

 

Whereas, Executive is currently a full-time employee of the Company; and

 

Whereas, the Company desires for Executive to continue to provide services to the Company, and wishes to provide Executive with certain compensation and benefits in return for such employment services; and

 

Whereas, Executive wishes to continue to be employed by the Company and to provide personal services to the Company in return for certain compensation and benefits;

 

Now, Therefore, in consideration of the mutual promises and covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereto agree as follows:

 

1. Employment by the Company.

 

1.1 Term. The Executive’s employment pursuant to this Agreement commenced on the Effective Date, and shall continue until terminated in accordance as provided in Section 4 (the “Contract Term”). Subject to the terms contained herein, Executive’s employment shall be “at-will” and may be terminated by either side, with or without notice, and without further obligation thereof.

 

1.2 Position. Executive shall continue to serve as the Company’s Chief Operating Officer. During Executive’s employment with the Company, Executive will devote Executive’s best efforts and substantially all of Executive’s business time and attention to the business of the Company, except for approved vacation periods and reasonable periods of illness or other incapacities permitted by the Company’s general employment policies.

 

1.3 Duties and Location. Executive shall report to the Chief Executive Officer or a designee thereof. Notwithstanding the foregoing, the Company reserves the right to change Executive’s direct report and assign other or additional duties or modify duties from time to time. Executive’s primary office location shall be the Company’s office located in Farmingdale, New York. The Company reserves the right to reasonably require Executive to perform Executive’s duties at places other than Executive’s primary office location from time to time, and to require business travel.

 

1.4 Policies and Procedures. The employment relationship between the Parties shall be governed by the general employment policies and practices of the Company. Executive shall at all times comply with all applicable laws, rules, and regulations, including those promulgated by regulatory and self-regulatory authorities, securities exchanges, and domestic and foreign agencies and authorities, as well as the Employee Handbook, the Compliance Manual and any other internal policies and procedures established by the Company and made available to employees generally.

 

 

 

 

2. Compensation.

 

2.1 Salary. For services to be rendered hereunder, Executive shall receive a base salary at the rate of $280,000 per year (the “Base Salary”), subject to standard payroll deductions and withholdings and payable in accordance with the Company’s regular payroll schedule. Executive’s base salary may be reviewed and changed by the Company on notice to the Executive.

 

2.2 Annual Bonus. Executive will be eligible for an annual discretionary bonus (the “Annual Bonus”), which will be based on a fiscal year basis, unless otherwise determined by the Company (the “Bonus Period”). Executive’s target for each Annual Bonus shall be 50% of Executive’s Base Salary (“Target”); provided, however, whether Executive receives an Annual Bonus for any Bonus Period, and the amount of any such Annual Bonus, whether at, above, or below Target will be determined by the Board or the compensation committee thereof in its sole discretion. The Annual Bonus, if payable, will be paid when bonuses are paid to similarly situated executives, which shall be prior to seventy-five days following the conclusion of the Bonus Period. For the avoidance of doubt, Executive will not be eligible for, and will not earn, any Annual Bonus if Executive’s employment terminates for any reason before the Annual Bonus is to be paid, except Executive shall remain eligible for such Annual Bonus only if Executive’s employment is terminated without Cause or if Executive resigns for Good Reason subsequent to the conclusion of the Bonus Period but prior to the payment date of the Annual Bonus, as more specifically stated herein. Any Annual Bonus paid for any year shall not create any entitlement to a bonus in a future year.

 

2.3 Sign-On Bonus. On or about the first regular payroll run date following the Effective Date, Executive received a sign-on bonus in the amount of $40,000, less applicable deductions and withholdings (the “Sign-On Bonus”). Executive agree that in the event of Executive’s termination for Cause or if Executive provides notice of Executive’s intent to terminate her employment without Good Reason, in each case prior to the date that is three (3) months after the first date of the Contract Term, Executive shall be required to immediately re-pay to the Company the gross amount of the Sign-On Bonus. This re-payment obligation shall not be deemed to be exclusive of any other rights and remedies available to the Company.

 

2.4 Sign-On Equity Grant. Subject to the approval of the Board and pursuant to the Company’s 2011 Amended and Restated Incentive Plan (the “Plan”), Executive will be eligible to receive an option to purchase 87,500 shares (“Options”) of the Company’s common stock at the fair market value as determined by the Board as of the date of grant (the “Option Grant”). The Option Grant shall vest in equal one-third annual increments, with the first vesting on the first anniversary of the grant date provided Executive remains employed in good standing on any such vesting date, and in all cases subject to the terms of the Plan and the Company’s Option grant documents, the execution of which by Executive is required for any such grant.

 

2

 

 

2.5 Annual Equity Grant. For each year of employment, subject to the approval of the Board and pursuant to the Plan, as hereinafter amended, restated, or replaced, Executive shall be eligible for grants thereunder in an amount and pursuant to terms as determined by the Board in its sole discretion. Each annual grant provided hereunder, if any, shall vest on terms as provided by the Company and shall be subject to the terms of the Plan and the Company’s Option grant documents, the execution of which by Executive is required for any such grant. Nothing herein requires the Board to make any grant under the Plan or otherwise.

 

3. Transaction Bonus.

 

3.1 Effective as of the Amendment Date, during the Contract Term, and provided Executive is still employed by the Company and has not given notice of her intent to terminate her employment, upon consummation of a Change in Control (as defined herein) or sale of an Operating Subsidiary, in addition to any other payments or benefits applicable thereto under this Agreement, Executive shall be eligible to receive a Transaction Bonus equal to three quarters of one percent (0.75%) of the “Transaction Value”, which means the total amount of Sale Proceeds paid in respect of the transaction that resulted in the Change in Control or sale of an Operating Subsidiary. Said Transaction Bonus shall be paid 50% as soon as practicable following the closing date of the Change in Control or sale of an Operating Subsidiary and 50% on the first anniversary thereof and shall be paid in the same form of consideration (e.g. cash, stock in the acquiring company, promissory note or a combination thereof) as is the consideration received by the holders of the majority of the outstanding voting securities of the Company who participate in the Transaction; provided, however, the Company reserves the right to pay the Transaction Bonus in such other form as it determines in its sole discretion. For the sake of clarity, the computation of the Transaction Bonus and whether Executive is eligible to receive same shall be determined in the Company’s sole discretion. Executive must be employed on the payment date of either portion of the Transaction Bonus in order to be eligible for same, provided, however, that such requirement shall not apply in the event that, after a Change in Control or sale of an Operating Subsidiary but before payment of the remaining 50% of the Transaction Bonus is paid, the Company terminates Executive’s employment without Cause or Executive terminates her employment for Good Reason, in either case Executive shall receive the Transaction Bonus on the anniversary of the Change in Control or sale of an Operating Subsidiary as if Executive were still employed, subject to the terms of Section 6. For the sake of clarity, “Sale Proceeds” shall mean the fair market value of the gross consideration received by the Company or its stockholders in the Change in Control or sale of an Operating Subsidiary transaction, as determined by the Company in its sole discretion immediately prior to the consummation of the Change in Control or sale of an Operating Subsidiary, taking into account such factors as the Committee deems appropriate, and less, in case of the initial transaction, (a) cash or cash equivalents held by the Company as of the date of the Change in Control or sale of an Operating Subsidiary, and (b) any expenses attributable to the Change in Control or sale of an Operating Subsidiary.

 

3.2 “Change in Control” shall mean, in respect of the Company any of (i) the beneficial ownership (as defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) of securities representing more than 50% of the combined voting power of Enzo is acquired by any “person” as defined in sections 13(d) and 14(d) of the Exchange Act (other than the Company, any subsidiary of the Company, or any trustee or other fiduciary holding securities under an employee benefit plan of the Company), (ii) the merger or consolidation of Enzo with or into another corporation where the shareholders of the Company, immediately prior to the consolidation or merger, would not, immediately after the consolidation or merger, beneficially own (as such term is defined in Rule 13d-3 under the Exchange Act), directly or indirectly, shares representing in the aggregate 50% or more of the combined voting power of the securities of the corporation issuing cash or securities in the consolidation or merger (or of its ultimate parent corporation, if any) in substantially the same proportion as their ownership of the Company immediately prior to such merger or consolidation, or (iii) the sale or other disposition of all or substantially all of Enzo’s assets to an entity, other than a sale or disposition by the Company of all or substantially all of Enzo’s assets to an entity, at least 50% of the combined voting power of the voting securities of which are owned directly or indirectly by shareholders of the Company, immediately prior to the sale or disposition, in substantially the same proportion as their ownership of the Company. “Operating Subsidiary” shall mean, a major division of the Company through which the parent Company directly or indirectly conducts a portion of its business, or company assets.

 

3

 

 

4. Company Benefits. Executive shall be eligible to participate in all employee benefit programs for which Executive is eligible under the terms and conditions of the benefit plans that may be in effect from time to time and provided by the Company to its senior-level employees including medical and dental insurance, life and disability insurance, and participation in the Company’s 401(k) retirement plan. During the Contract Term, Executive shall further receive paid vacation and a car allowance as determined by the Company in its sole discretion. The Company reserves the right to cancel or change the benefit plans or programs it offers to the Executive at any time; provided, however, that any such change shall be across the board changes similarly affecting the eligibility requirements of all senior-level employees of the Company.

 

5. Termination of Employment; Severance.

 

5.1 Employment. During the Contract Term, either Executive or the Company may terminate Executive’s employment relationship at any time, provided, however, that if Executive resigns during the Contract Term, Executive shall provide no less than ninety (90) days’ advance written notice of any such termination (the “Notice Period”). During the Notice Period, Executive shall remain an employee of the Company, and shall continue to receive Base Salary, but no other compensation. The Company may elect to have Executive not report to work for all or any portion of such Notice Period. The Company shall have the right, at its sole discretion, to accelerate Executive’s termination date to any date subsequent to receiving written notice from Executive, and thus conclude the Notice Period.

 

5.2 Termination Without Cause or Good Reason

 

a. The Company may terminate Executive’s employment with the Company at any time with or without Cause (as defined below) during the Contract Term.

 

b. If Executive’s employment is terminated by the Company without Cause, or if Executive terminates her employment with Good Reason, the Company shall pay Executive, as severance, (x) the equivalent of twelve (12) months of Executive’s Base Salary and (y) if the termination date occurs subsequent to the conclusion of the fiscal year but prior to the payment of the Annual Bonus to which the fiscal year relates, such Annual Bonus, if any, as computed in accordance with Section 2.2 above, subject to standard payroll deductions and withholdings (the “Severance”). The Severance will be paid as a continuation on the Company’s regular payroll, beginning no later than the first regularly-scheduled payroll date following the sixtieth (60th) day after Executive’s Separation from Service (as defined below), provided the Separation Agreement (as discussed in Paragraph 5) has become effective and further provided that the Bonus component under (y), if any, shall be paid in a lump sum on the sixtieth day after Executive’s Separation from Service.

 

4

 

 

c. Any stock options held by Executive as of the Effective Date of the Agreement or hereinafter granted shall provide for full vesting provided Executive’s employment is terminated without Cause or if Executive terminates her employment with Good Reason, or as a result of a Change in Control, subject to any other terms as provided in the Company’s incentive compensation program. Furthermore, all restricted stock units shall become unrestricted immediately upon termination without Cause or Change in Control.

 

d. For purposes of this Agreement, “Cause” for termination will mean: (a) commission of any (i) felony or (ii) crime involving fraud, dishonesty or moral turpitude (whether or not a felony); (b) any action by Executive involving fraud, breach of the duty of loyalty, malfeasance, willful misconduct, or negligence, (c) the failure or refusal by Executive to perform any material duties hereunder or to follow any lawful and reasonable direction of the Company; (d) intentional damage to any property of the Company; (e) chronic neglect or absenteeism in the performance of Executive’s duties; (f) willful misconduct, gross negligence, or other material violation of Company policy or code of conduct that causes an adverse effect upon the Company; (g) breach of any written agreement with the Company (including this Employment Agreement); or (h) any action that in the reasonable belief of the Board shall or potentially shall subject the Company to material adverse publicity or effects. Prior to any termination for Cause under section (c), (e), (0, (g), or (h), the Board shall provide Executive by written notice with ten (10) calendar days to cure same, provided any such actions underlying Cause are determined by the Board to be curable. Any determination of Cause hereunder shall be made by the Board in its good faith discretion, which shall only be made by the Board and, to the extent deemed practicable by the Board, after providing the Executive an opportunity to respond to any determination or allegation of Cause.

 

5.3 For purposes of this Agreement, “Good Reason” for termination will mean: (i) material diminution of the Executive’s title or duties below that of the level of a Chief Operating Officer; (ii) a material reduction in Executive’s Base Salary, other than as required by exigent business circumstances; (iii) the Company requiring Executive to work on a full-time basis outside of the state of New York; or (iv) a material and uncured breach by the Company of any provision of this Agreement. provided, that Executive shall give written notice to the Company within thirty (30) days following the occasion of any allegation of Good Reason, and the Company shall have thirty (30) days to cure same. In the event such occurrence is not cured, then Executive may terminate Executive’s employment for Good Reason hereunder within ninety (90) days from the end of the cure period. The Executive’s continued employment prior to the conclusion of the ninety (90) day period stated in the preceding sentence shall not constitute consent to, or waiver of rights with respect to, any act or failure to act by the Company constituting “Good Reason” hereunder, if not cured in the preceding thirty day period.

 

5

 

 

5.4 Termination for Any Other Reason.

 

a. Upon a termination for any reason other than without Cause or with Good Reason, then upon Executive’s termination date all payments of compensation by the Company to Executive hereunder will terminate immediately (except as to amounts already earned), and Executive will not be entitled to any Severance.

 

b. In the event of termination for any reason, Executive shall resign from all positions and terminate any relationships as an employee, advisor, officer or director with the Company and any of its affiliates, each effective on the date of termination.

 

6. Conditions to Receipt of Severance Benefits. In order to receive any Severance Benefits, the termination of Executive’s employment must constitute a “separation from service” (as defined under Treasury Regulation Section 1.409A-1(h), without regard to any alternative definition thereunder, a “Separation from Service”), and Executive must be in compliance with the terms of this Agreement. Further, the receipt of the Severance Benefits will be conditioned on Executive signing, not revoking, and complying with a separation agreement and release of claims in a form reasonably satisfactory to the Company (the “Separation Agreement”). No Severance Benefits will be paid or provided until the Separation Agreement becomes effective.

 

7. Section 409A. It is intended that all of the Severance and other payments payable under this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Code Section 409A provided under Treasury Regulations 1.409A-1(b)(4), 1.409A-1(b)(5) and 1.409A-1(b)(9), and this Agreement will be construed to the greatest extent possible as consistent with those provisions, and to the extent not so exempt, this Agreement (and any definitions hereunder) will be construed in a manner that complies with Section 409A. For purposes of Code Section 409A (including, without limitation, for purposes of Treasury Regulation Section 1.409A-2(b)(2)(iii)), Executive’s right to receive any installment payments under this Agreement (whether severance payments, reimbursements or otherwise) shall be treated as a right to receive a series of separate payments and, accordingly, each installment payment hereunder shall at all times be considered a separate and distinct payment.

 

8. Restrictive Covenants

 

8.1 Definitions. The following capitalized terms used in this Agreement shall have the meanings assigned to them below, which definitions shall apply to both the singular and the plural forms of such terms:

 

i. Confidential Information” “Confidential Information” shall be given its broadest possible interpretation and shall mean any and all information of the Company, its affiliates, subsidiaries, and parents (each, a “Company Entity”, and collectively, “Company Entities”), including without limitation: (i) financial and business information relating to any Company Entity, such as information with respect to costs, fees, profits, revenues, markets, mailing/client lists, strategies and plans for future business, new business, product or other development, potential acquisitions or divestitures and new marketing ideas; (ii) product and technical information relating to any Company Entity, such as software, software codes, computer models and research and development projects; (iii) customer or investor information, such as the identity of any Company Entity’s clients or investors, the names of representatives of Company Entity customer or investors responsible for entering into contracts with a Company Entity, the amounts paid by such investors or customers to any Company Entity, specific customer or investor needs and requirements, specific customer or investor risk characteristics, and specific customer or investor preferences; (iv) personnel information, such as the identity and number of any Company Entity’s other employees and officers, their salaries, bonuses, benefits, skills, qualifications, and abilities; (v) any and all information in whatever form relating to any customer or prospective customer of a Company Entity, including but not limited to its business, employees, operations, systems, assets, liabilities, finances, products, and marketing, selling and operating practices; (vi) any information related to any security system of any Company Entity or any of employees, (vii) any and all information pertaining to the business and or personal affairs of the Company’s partners, members and employees, including but not limited to their personal lives, characteristics, opinions, ideas, conduct, habits or background or their business or financial condition, affairs, dealings or operations or their personal database, personal photographs or videotapes, purchases, travel itineraries, social interactions, tax information, emails, private conversations, phone calls and correspondence; (viii) any information not included in (i) through (vii), above, which the Employee knows or should know is subject to a restriction on disclosure or which the Employee knows or should know is considered by any Company Entity’s clients or prospective clients to be confidential, sensitive, proprietary, or a trade secret or is not readily available to the public; or (ix) intellectual property, including inventions and copyrightable works. Confidential Information is not generally known or available to the general public, but has been developed, compiled, or acquired by the Company at its effort and expense. Confidential Information can be in any form, including but not limited to verbal, written, or machine readable, including electronic files. By way of example but not limitation of the foregoing, Confidential Information may be acquired by observing documents, things, people or events, by direct communication with clients or others or by overhearing conversations in person or over the telephone or otherwise. “Confidential Information” shall not include information that has become generally available to the public by the act of one who has the right to disclose such information without violating any right or privilege of the Company.

 

ii. Restricted Period” from the Start Date through the twelvemonth anniversary of Executive’s Termination Date.

 

iii. Person” means any individual or any corporation, partnership, joint venture, limited liability company, association or other entity or enterprise.

 

iv. Restricted Business” means any person, business, entity, organization or group within a larger firm that engages in, or plans to engage in, (i) those parts of the business of the Company and any Company Entity with which you were involved during the employment or about which you received Confidential Information, or (ii) any business activity which the Company or any Company Entity was actively planning to engage in as of the Termination Date;

 

6

 

 

v. Restrictive Covenants” means the covenants contained in this Section 8.

 

vi. Termination” means the termination of Executive’s employment with the Company, for any reason, whether with or without Cause, upon the initiative of either party.

 

vii. Termination Date” means the date of Executive’s Termination.

 

viii. Work Product” means all memoranda, summaries, written work product, business plans, formulas, recipes, inventions, innovations, improvements, developments, methods, designs, analyses, drawings, reports and all similar or related information (whether patentable or not) that are based upon Confidential Information and that are conceived, developed or made by Executive during her employment.

 

8.2 Restriction on Disclosure and Use of Confidential Information. Executive agrees that Executive shall not, directly or indirectly, use any Confidential Information on Executive’s own behalf or on behalf of any Person other than the Company, or reveal, divulge, or disclose any Confidential Information to any Person not expressly authorized by the Company to receive such Confidential Information. This obligation shall remain in effect for as long as the information or materials in question retain their status as Confidential Information. Executive further agrees that he shall fully cooperate with the Company in maintaining the Confidential Information to the extent permitted by law. The parties acknowledge and agree that this Agreement is not intended to, and does not, alter either the Company’s rights or Executive’s obligations under any state or federal statutory or common law regarding trade secrets and unfair trade practices. Anything herein to the contrary notwithstanding, Executive shall not be restricted from: (i) disclosing information that is required to be disclosed by law, court order or other valid and appropriate legal process: provided, however, that in the event such disclosure is required by law, Executive shall provide the Company with prompt notice of such requirement so that the Company may seek an appropriate protective order prior to any such required disclosure by Executive; or (ii) reporting possible violations of federal, state, or local law or regulation to any governmental agency or entity, or from making other disclosures that are protected under the whistleblower provisions of federal, state, or local law or regulation, and Executive shall not need the prior authorization of the Company to make any such reports or disclosures and shall not be required to notify the Company that Executive has made such reports or disclosures. Notwithstanding anything in the foregoing to the contrary, in accordance with the Defend Trade Secrets Act of 2016, Executive will not be criminally or civilly liable for disclosing a trade secret if it was disclosed: (1) to any government official or attorney in confidence directly or indirectly for the sole purpose of reporting or investigating a suspected violation of law; (2) in a complaint or other document filed in a lawsuit or other proceeding if filed under seal; or (3) to an attorney or used in a court proceeding in a retaliation lawsuit if any document containing a trade secret is filed under seal and is not disclosed except pursuant to court order.

 

8.3 Non-Competition. The Executive acknowledges and agrees that solely by reason of employment by the Company, the Executive has and will come into contact with a significant number of the Company’s customers and prospective customers and have access to Confidential Information (as defined herein) and trade secrets relating thereto, including those regarding the Company’s clients, prospective clients, proprietary business models and strategies, and related information. Consequently, the Employee covenants and agrees that during the Restricted Period, Executive shall not directly or indirectly, an individual proprietor, partner, stock-holder, officer, employee, director, joint venturer, investor, lender, or in any other capacity whatsoever (other than as the holder of not more than three percent (3%) of the total outstanding stock of a publicly held company), engage in the Restricted Business.

 

7

 

 

8.4 Non-Solicitation. Executive agrees that, during the Restricted Period, he shall not, directly or indirectly, in her own capacity or through any other entity or person: (i) solicit, persuade or induce any investor of the Company to terminate, reduce, disrupt or refrain from renewing or extending its contractual or other relationship with the Company in regard to the purchase of products or services, procured, performed, manufactured, marketed, or sold, by the Company; (ii) in any way interfere with the relationship between any such investor, client, supplier, licensee, licensor, franchisee or business relation of the Company and/or any of its affiliates; (iii) induce or attempt to induce any employee of the Company or any of its affiliates to leave the employ of the Company and/or any of its affiliates, or in any way interfere with the relationship between the Company and/or any of its affiliates on the one hand and any employee thereof on the other hand; or (iv) solicit to hire (other than through general advertisements for employment not directed at employees of the Company or any of its affiliates) or hire any person who was an employee of any of the Company or any of its affiliates at any time during the one (1) year preceding such solicitation.

 

8.5 Non-Disparagement. Executive agrees that, at any time hereinafter, Executive will not do or say anything, including but not limited to communicating on the internet (including but not limited to any posting or reference on any social networking site), or via e-mail, telephone, face-to-face communication, or otherwise, that (i) criticizes or disparages the Company or its management, practices, policies, products or services; (ii) disrupts or impairs the normal, ongoing business operations of Company, or any member of the Company Group; or (iii) harms the business reputation of Company or the Company Group with its employees, customers, suppliers, contractors or the public. Executive will not discuss any information (whether confidential or not) about the Company with any reporter, author, producer, or similar person or entity, or take any other action seeking to publicize or disclose any such information in any way likely to result in such information being made available to the general public in any form, including books, articles or writings of any kind, as well as film, videotape, audiotape or any other medium or as commonly provided on a resume. Executive acknowledges and agree that these prohibitions extend to statements, written or verbal, made to anyone and includes statements made via social media including on blogs or social networking sites, including but not limited to Facebook, LinkedIn, or Twitter. Neither the Board nor the Company or any of its affiliates shall authorize any disparaging comments about Executive. Notwithstanding the foregoing, nothing in this paragraph shall prevent either Executive, the Board or the Company or any of its affiliates from making any truthful statement to the extent necessary with respect to any litigation, arbitration, or mediation involving this Agreement, including, but not limited to, enforcement of this Agreement or as required by law or by any court, arbitrator, mediator, or administrative or legislative body with actual or apparent jurisdiction to order such person to disclose or make accessible such information.

 

8

 

 

8.6 Return of Materials. Executive agrees that she will not retain or destroy (except as set forth below), and will immediately return to the Company on or, if specifically requested, prior to the Termination Date, or at any other time the Company requests such return, any and all Company property, including Confidential Information and all other documents, materials, information, and property, including but not limited to memoranda, letters, notes, plans, reports, analyses, recaps, jump drives, disks, tapes, journals, notebooks, and any Company-provided computer, cell phone, Blackberry, beeper, keys, key fob, security card, phone card, credit cards, computer user name and password, and/or voicemail code, all other files and documents relating to the Company and its business (regardless of form, but specifically including all electronic files and data of the Company). Executive will not make, distribute, or retain copies of any such information or property. Executive agrees that the ownership and right of control of all programs, databases, electronic files, reports, records and supporting documents prepared by, for or on behalf of Executive in connection with the performance of Executive’s duties during her employment are vested exclusively in the Company and remain the exclusive property of the Company.

 

8.7 Inventions. Executive acknowledges and agrees that any and all Work Product, products, improvements, and inventions or creations conceived or made by Executive during the period of Executive’s employment with the Company relating to the activities or business of the Company or the Company Group are the sole and exclusive property of the Company or its nominee. Executive shall promptly disclose any Work Product to the Company and perform all acts and things and sign whatever documents and agreements are necessary to confirm and vest the entire right, title and interest in such Work Product in the Company, including copyright assignments, patent applications and other documents and papers. Any assignment of Work Product includes all rights of attribution, paternity, integrity, modification, disclosure and withdrawal, and any other rights throughout the world that may be known as or referred to as “moral rights,” “artist’s rights,” “droit moral” or the like (collectively, “Moral Rights”). To the extent that Moral Rights cannot be assigned under applicable law, Executive hereby waives and agrees not to enforce any and all Moral Rights, including, without limitation, any limitation on subsequent modification, to the extent permitted under applicable law. Executive agrees to assist the Company, or its designee, at its expense, in every proper way to secure the Company’s, or its designee’s, rights in the Company Inventions and any copyrights, patents, trademarks, mask work rights, Moral Rights, or other intellectual property rights relating thereto in any and all countries, including the disclosure to the Company or its designee of all pertinent information and data with respect thereto, the execution of all applications, specifications, oaths, assignments, recordations, and all other instruments which the Company or its designee shall deem necessary in order to apply for, obtain, maintain and transfer such rights, or if not transferable, waive and agree never to assert such rights, and in order to assign and convey to the Company or its designee, and any successors, assigns and nominees the sole and exclusive right, title and interest in and to such Company Inventions, and any copyrights, patents, mask work rights or other intellectual property rights relating thereto. Executive hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as Executive’s agent and attorney-in-fact, to act for and in Executive’s behalf and stead to execute and file any such instruments and papers and to do all other lawfully permitted acts to further the application for, prosecution, issuance, maintenance or transfer of patent, copyright, mask work and other registrations related to such Work Product. These obligations shall be binding upon Executive and Executive’s heirs, assigns, executors, administrators, agents or other legal representatives. Executive may not use, disclose to third parties or otherwise retain any such works or inventions, without the prior written permission of the Company.

 

9

 

 

8.8 Cooperation. The Executive shall cooperate with the Company and its counsel in connection with any litigation or regulatory or self-regulatory inquiry, investigation or proceeding relating to activities of Executive, or by activities of others of which the Executive may have knowledge, and this obligation shall survive the termination of this Agreement. The Company shall reimburse the Executive for reasonable out-of-pocket travel and other reasonable incidental expenses (other than legal expenses unless such legal expenses are requested by the Executive as a result of divergent interests between Executive and the Company, and approved by the Board in writing) incurred as a result of the Executive’s cooperation pursuant to the immediately preceding sentence.

 

8.9 Exceptions. Nothing in this Agreement shall limit the rights of any government agency or any party’s right of access to, participation or cooperation with any government agency. Notwithstanding anything to the foregoing, nothing herein, or in any other agreement or policy, shall limit Executive’s right under applicable law to file a charge or complaint with the U.S. Equal Employment Opportunity Commission, the National Labor Relations Board, the Occupational Safety and Health Administration, the Securities and Exchange Commission, or any other federal, state or local governmental agency or commission (“Government Agencies”). Executive further understands that this Agreement does not limit her ability to communicate with any Government Agencies or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including providing documents or other information, without notice to the Company. This Agreement does not limit Executive’s right to receive an award for information provided to any Government Agencies.

 

8.10 Enforcement of Restrictive Covenants.

 

i. Rights and Remedies Upon Breach. The parties specifically acknowledge and agree that the remedy at law for any breach of the Restrictive Covenants will be inadequate, and that in the event Executive breaches, or threatens to breach, any of the Restrictive Covenants, the Company shall have the right and remedy, without the necessity of proving actual damage or posting any bond, to enjoin, preliminarily and permanently, Executive from violating or threatening to violate the Restrictive Covenants and to have the Restrictive Covenants specifically enforced by any court of competent jurisdiction, it being agreed that any breach or threatened breach of the Restrictive Covenants would cause irreparable injury to the Company and that money damages would not provide an adequate remedy to the Company.

 

ii. Severability and Modification of Covenants. Executive acknowledges and agrees that each of the Restrictive Covenants is reasonable and valid in time and scope and in all other respects. The parties agree that it is their intention that the Restrictive Covenants be enforced in accordance with their terms to the maximum extent permitted by law. Each of the Restrictive Covenants shall be considered and construed as a separate and independent covenant. Should any part or provision of any of the Restrictive Covenants be held invalid, void, or unenforceable, such invalidity, voidness, or unenforceability shall not render invalid, void, or unenforceable any other part or provision of this Agreement or such Restrictive Covenant. If any of the provisions of the Restrictive Covenants should ever be held by a court of competent jurisdiction to exceed the scope permitted by the applicable law, such provision or provisions shall be automatically modified to such lesser scope as such court may deem just and proper for the reasonable protection of the Company’s legitimate business interests and may be enforced by the Company to that extent in the manner described above and all other provisions of this Agreement shall be valid and enforceable. The Restrictive Covenants shall survive the termination of the Contract Term and this Agreement.

 

10

 

 

9. Governing Law; Dispute Resolution. The interpretation and application of this Employment shall be governed by the laws of the State of New York without regard to principles of conflict of laws, other than laws which violate a fundamental public policy of the state of employ, in which case such state’s laws shall govern with regard to such policies. Except for claims requesting injunctive relief, any dispute or claim arising out of, in connection with, or relating to this Agreement (including without limitation its subject matter, interpretation, or formation) or to Executive’s employment or relationship with the Company shall be resolved by binding arbitration to be held in or around Farmingdale, New York, before three (3) arbitrators selected by the American Arbitration Association, conducted in accordance with the then-prevailing Employment Arbitration Rules and Mediation Procedures of the American Arbitration Association. A copy of these rules can be accessed through the American Arbitration Association’s website (www.adr.org). The arbitrators’ decision will be final and binding in accordance with the Federal Arbitration Act and may be enforced in any court of competent jurisdiction. The arbitrators will not have the right to modify or change any of the terms of this Employment Agreement. The arbitrators, and not any court, shall have exclusive authority to resolve any dispute relating to the interpretation, applicability, enforceability or formation of this Employment Agreement including any claim that all or any part of this Agreement is void or voidable. The parties agree that the arbitrators may provide all appropriate remedies at law and equity and will have the power to summarily adjudicate claims and/or enter summary judgment in appropriate cases. In any arbitration proceeding conducted pursuant to this paragraph, the parties shall have the right to discovery, to call witnesses, and to cross-examine the other party’s witnesses. The arbitrator shall render a final decision in writing, setting forth the reasons for the arbitration award. Both parties are bound by this agreement to arbitrate, but it does not include disputes, controversies or differences which may not by law be arbitrated. The parties agree that the arbitration proceedings described in this Section are to be treated as confidential, and that the parties will act to protect the confidentiality of the documents, facts, and proceedings related to the arbitration. THE PARTIES WAIVE THEIR RIGHT TO HAVE ANY SUCH DISPUTE, CLAIM OR CONTROVERSY DECIDED BY A JUDGE OR JURY IN A COURT. THE PARTIES ALSO AGREE THAT EACH MAY BRING CLAIMS AGAINST THE OTHER ONLY IN THEIR INDIVIDUAL CAPACITIES, AND NOT AS A PLAINTIFF OR CLASS MEMBER IN ANY PURPORTED CLASS OR COLLECTIVE PROCEEDING. THE PARTIES ALSO AGREE THAT EACH MAY NOT BRING CLAIMS AGAINST THE OTHER IN ANY PURPORTED REPRESENTATIVE ACTION, EXCEPT TO THE EXTENT THIS STATEMENT IS UNENFORCEABLE UNDER THE LAW. All American Arbitration Association filing fees, administrative costs, and arbitrator fees (as well as other related fees) shall be paid by the Company, with the exception of fees that would be paid by the Executive should the dispute be settled in a Court of Law.

 

11

 

 

10. General Provisions.

 

10.1 Notices. Any notices provided must be in writing and will be deemed effective upon the earlier of personal delivery, email, or the next day after sending by overnight carrier, to the Company at its primary office location and to Executive at the address as listed on the Company payroll.

 

10.2 Severability. Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced in such jurisdiction to the extent possible in keeping with the intent of the parties.

 

10.3 Waiver. Any waiver of any breach of any provisions of this Agreement must be in writing to be effective, and it shall not thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement.

 

10.4 Complete Agreement. This Agreement constitutes the entire agreement between Executive and the Company with regard to this subject matter and is the complete, final, and exclusive embodiment of the Parties’ agreement with regard to this subject matter, inclusive of any earlier offer letter. This Agreement is entered into without reliance on any promise or representation, written or oral, other than those expressly contained herein, and it supersedes any other such promises, warranties or representations. It is entered into without reliance on any promise or representation other than those expressly contained herein, and it cannot be modified or amended except in a writing signed by a duly authorized officer of the Company.

 

10.5 Counterparts. This Agreement may be executed in separate counterparts, any one of which need not contain signatures of more than one party, but all of which taken together will constitute one and the same Agreement.

 

10.6 Headings. The headings of the paragraphs hereof are inserted for convenience only and shall not be deemed to constitute a part hereof nor to affect the meaning thereof

 

10.7 Successors and Assigns. This Agreement is intended to bind and inure to the benefit of and be enforceable by Executive and the Company, and their respective successors, assigns, heirs, executors and administrators. The Company may freely assign this Agreement, without Executive’s prior written consent. Executive may not assign any of her duties hereunder and she may not assign any of her rights hereunder without the written consent of the Company. The Company will require any successor (whether direct or indirect, by purchase, merger, consolidation, assign or otherwise) to all or substantially all of the business and/or assets of the Company to assume expressly and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place. As used in this Agreement, “Company” shall mean the Company as hereinbefore defined and any successor to its business and/or assets as aforesaid.

 

10.8 Background Check and Ability to Work. This offer of employment is contingent upon verification of Executive’s identity and authorization to legally work in the United States, a background and reference check, and all other Company practices and procedures as reasonably requested by the Company.

 

1.9 Tax Withholding. All payments and awards contemplated or made pursuant to this Agreement will be subject to withholdings of applicable taxes in compliance with all relevant laws and regulations of all appropriate government authorities. Executive acknowledges and agrees that the Company has neither made any assurances nor any guarantees concerning the tax treatment of any payments or awards contemplated by or made pursuant to this Agreement. Executive has had the opportunity to retain a tax and financial advisor and fully understands the tax and economic consequences of all payments and awards made pursuant to the Agreement.

 

***

 

12

 

 

You acknowledge and agree that you have read and understand this Employment agreement and you voluntarily agree to the terms and conditions contained herein.

 

We look Forward to you continuing your employment with the Company. If you accept this amended offer of employment, please sign and return to me this amended and restated Employment Agreement attached by no later than november 2, 2022 or this offer shall expire.

 

In Witness Whereof, the Parties have executed this Agreement on the day and year first written above.

 

  ENZO BIOCHEM INC.
   
  By: /s/ Hamid Erfanian
   
  Executive
   
  /s/ Kara Cannon

 

 

13

 

 

 

EX-10.2 3 ea167979ex10-2_enzobio.htm SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT BETWEEN ENZO BIOCHEM, INC. AND HAMID ERFANIAN, EFFECTIVE AS OF OCTOBER 20, 2022

Exhibit 10.2

 

SECOND AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT

 

This Second Amended and Restated Executive Employment Agreement (the “Agreement”), dated as of October 14, 2021 (the “Effective Date”), as amended March 24, 2022 and further amended October 20, 2022 (the “Amendment Date”), made between Enzo Biochem, Inc., a New York corporation, with its principal office at 527 Madison Avenue, New York, New York 10022, (the “Company”) and Hamid Erfanian (the “Executive”) (collectively, the “Parties”).

 

Whereas, the Company desires for Executive to provide services to the Company, and wishes to provide Executive with certain compensation and benefits in return for such employment services; and

 

Whereas, Executive wishes to be employed by the Company and to provide personal services to the Company in return for certain compensation and benefits;

 

Now, Therefore, in consideration of the mutual promises and covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereto agree as follows:

 

1. Employment by the Company.

 

1.1 Position. Executive shall serve as the Company’s Chief Executive Officer. Executive’s employment with the Company began on November 8, 2021 (the “Start Date”). During Executive’s employment with the Company, Executive will devote Executive’s best efforts and substantially all of Executive’s business time and attention to the business of the Company, except for approved vacation periods and reasonable periods of illness or other incapacities permitted by the Company’s general employment policies. Executive may engage in civic and not-for-profit activities and serve as a board member on board of directors of noncompetitive publicly traded companies, in each case, so long as such activities do not materially interfere with the performance of Executive’s duties hereunder, as reasonably determined by the Board of Directors (the “Board”).

 

1.2 Duties and Location. Executive shall report to the Board or a designee thereof. Notwithstanding the foregoing, the Company reserves the right to change Executive’s direct report and assign other or additional duties or modify duties from time to time. Executive’s primary office location shall be the Company’s office located in Farmingdale, New York. The Company reserves the right to reasonably require Executive to perform Executive’s duties at places other than Executive’s primary office location from time to time, and to require business travel.

 

1.3 Policies and Procedures. The employment relationship between the Parties shall be governed by the general employment policies and practices of the Company. Executive shall at all times comply with all applicable laws, rules, and regulations, including those promulgated by regulatory and self-regulatory authorities, securities exchanges, and domestic and foreign agencies and authorities, as well as the Employee Handbook, the Compliance Manual and any other internal policies and procedures established by the Company and made available to employees generally.

 

 

 

2. Compensation.

 

2.1 Salary. For services to be rendered hereunder, Executive shall receive a base salary at the rate of $600,000 per year (the “Base Salary”), subject to standard payroll deductions and withholdings and payable in accordance with the Company’s regular payroll schedule. Executive’s base salary may be reviewed and changed by the Company on notice to the Executive.

 

2.2 Annual Bonus Executive will be eligible for an annual discretionary bonus of between thirty percent (30%) and one hundred percent (100%) (the “Bonus Range”) of Executive’s Base Salary actually received in any such year (the “Annual Bonus”), which will be based on a fiscal year basis, unless otherwise determined by the Company (the “Bonus Period”). Whether Executive receives an Annual Bonus for any Bonus Period, and the amount of any such Annual Bonus, will be determined by the Board or the compensation committee thereof in its sole discretion, provided, however, that subject to the remainder of the provisions in this Section 2.2, Executive’s Annual Bonus payable in respect of any Bonus Period shall not be less than or higher than the Bonus Range. Executive must remain an active employee in good standing at the time the Annual Bonus is paid in order to earn an Annual Bonus for the prior Bonus Period. The Annual Bonus, if payable, will be paid when bonuses are paid to similarly situated executes, which shall be prior to seventy-five days following the conclusion of the Bonus Period. For the avoidance of doubt, Executive will not be eligible for, and will not earn, any Annual Bonus if Executive’s employment terminates for any reason before the Annual Bonus is to be paid, except as otherwise specifically stated in Section 4.2(b). Any Annual Bonus paid for any year shall not create any entitlement to a bonus in a future year.

 

2.3 Sign-On Equity Grant. Subject to the approval of the Board and pursuant to the Company’s 2011 Amended and Restated Incentive Plan (the “Plan”), Executive received (a) a restricted stock unit (“RSU”) award for 260,000 shares of the common stock of the Company (the “RSU Grant”); and (b) an option to purchase 700,000 shares (“Options”) of the Company’s common stock at the fair market value as determined by the Board as of the date of grant (the “Option Grant”). Each of the RSU Grant and the Option Grant shall vest in equal one-third annual increments, with the first vesting on the first anniversary of the grant date provided Executive remains employed in good standing on any such vesting date, and in all cases subject to the terms of the Plan and the Company’s Option and RSU grant documents, the execution of which by Executive is required for any such grant. Notwithstanding the foregoing, in the event of Executive’s termination without Cause (as defined herein), the RSU Grant and Option Grant, subject to terms of Section 5 herein, shall vest.

 

2.4 Annual Equity Grant. For each year of employment, subject to the approval of the Board and pursuant to the Plan, Executive shall be eligible for a grant of both RSUs and Options in an amount and pursuant to terms as determined by the Board in its sole discretion; provided, however, that in each year, the Board shall provide the Executive with individual and corporate performance metrics which it shall reasonably assess in determining such year’s grant. Each annual grant provided hereunder shall vest on terms as provided by the Company and shall be subject to the terms of the Plan and the Company’s Option and RSU grant documents, the execution of which by Executive is required for any such grant.

 

2

 

 

2.5 Relocation. As a condition of his employment hereunder, Executive shall relocate to the Farmingdale, New York area within six (6) months of the Start Date. The Company shall reimburse Executive for up to $60,000 in Relocation Expenses relating to such relocation. provided Executive provides evidence of incurring such costs to the reasonable satisfaction of the Company. For purposes hereof, “Relocation Expenses” shall mean reasonable expenses incurred by Executive related to costs associated with the sale of Executive’s old residence and the physical movement of all goods and vehicles that are in Executive’s current home. The foregoing notwithstanding, if within one (l) year of the relocation date, Executive’s employment with the Company is terminated either by the Company for Cause or voluntarily by Executive in the absence of a Good Reason, then Executive shall repay to the Company the amount of the actually-reimbursed Relocation Expenses multiplied by a fraction, the numerator of which equals the number of days from the effective date of such termination to the first anniversary of Executive’s relocation date and the denominator of which will be 365 (and the Company may withhold such amount from any payments otherwise due to Executive).

 

3. Transaction Bonus.

 

3.1 Effective as of the Amendment Date, during the term of Executive’s employment, and provided Executive is still employed by the Company and has not given notice of his intent to terminate his employment, upon consummation of a Change in Control (as defined herein) or sale of an Operating Subsidiary, in addition to any other payments or benefits applicable thereto under this Agreement, Executive shall be eligible to receive a Transaction Bonus equal to one and seven-tenths percent (1.7%) of the “Transaction Value”, which means the total amount of Sale Proceeds paid in respect of the transaction that resulted in the Change in Control or sale of an Operating Subsidiary. Said Transaction Bonus shall be paid 50% as soon as practicable following the closing date of the Change in Control or sale of an Operating Subsidiary and 50% on the first anniversary thereof and shall be paid in the same form of consideration (e.g. cash, stock in the acquiring company, promissory note or a combination thereof) as is the consideration received by the holders of the majority of the outstanding voting securities of the Company who participate in the Transaction; provided, however, the Company reserves the right to pay the Transaction Bonus in such other form as it determines in its sole discretion. For the sake of clarity, the computation of the Transaction Bonus and whether Executive is eligible to receive same shall be determined in the Company’s sole discretion. Executive must be employed on the payment date of either portion of the Transaction Bonus in order to be eligible for same provided, however, that such requirement shall not apply in the event that, after a Change in Control or sale of an Operating Subsidiary but before payment of the remaining 50% of the Transaction Bonus is paid, the Company terminates Executive’s employment without Cause or Executive terminates his employment for Good Reason, in either case Executive shall receive the Transaction Bonus on the anniversary of the Change in Control or sale of an Operating Subsidiary as if Executive were still employed, subject to the terms of Section 6. For the sake of clarity, “Sale Proceeds” shall mean the fair market value of the gross consideration received by the Company or its stockholders in the Change in Control of sale or an Operating Subsidiary transaction, as determined by the Company in its sole discretion immediately prior to the consummation of the Change in Control of sale or an Operating Subsidiary, taking into account such factors as the Committee deems appropriate, and less, in case of the initial transaction, (a) cash or cash equivalents held by the Company as of the date of the Change in Control of sale or an Operating Subsidiary, and (b) any expenses attributable to the Change in Control or sale of an Operating Subsidiary.

 

3

 

 

3.2 “Change in Control” shall mean, in respect of the Company any of (i) the beneficial ownership (as defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) of securities representing more than 50% of the combined voting power of Enzo is acquired by any “person” as defined in sections I3(d) and 14(d) of the Exchange Act (other than the Company, any subsidiary of the Company, or any trustee or other fiduciary holding securities under an employee benefit plan of the Company), (ii) the merger or consolidation of Enzo with or into another corporation where the shareholders of the Company, immediately prior to the consolidation or merger, would not, immediately after the consolidation or merger, beneficially own (as such term is defined in Rule 13d-3 under the Exchange Act), directly or indirectly, shares representing in the aggregate 50% or more of the combined voting power of the securities of the corporation issuing cash or securities in the consolidation or merger (or of its ultimate parent corporation, if any) in substantially the same proportion as their ownership of the Company immediately prior to such merger or consolidation, or (iii) the sale or other disposition of all or substantially all of Enzo’s assets to an entity, other than a sale or disposition by the Company of all or substantially all of Enzo’s assets to an entity, at least 50% of the combined voting power of the voting securities of which are owned directly or indirectly by shareholders of the Company, immediately prior to the sale or disposition, in substantially the same proportion as their ownership of the Company. “Operating Subsidiary” shall mean, a major division of the Company through which the parent Company directly or indirectly conducts a portion of its business, or company assets.

 

 

4. Company Benefits. Executive shall be eligible to participate in all employee benefit programs for which Executive is eligible under the terms and conditions of the benefit plans that may be in effect from time to time and provided by the Company to its senior-level employees, which as of the Start Date shall include, at minimum, health, medical & dental for the Executive and his spouse and dependents, 40l(k), and paid time off including four (4) weeks of paid vacation as well as other benefits, in each case pursuant to and subject to the existing policies and programs maintained by the Company, a summary of which shall be provided to the Executive for review together with this Agreement. The Company reserves the right to cancel or change the benefit plans or programs it offers to the Executive at any time; provided, however, that any such change shall be across the board changes similarly affecting the eligibility requirements of all senior-level employees of the Company.

 

5. Termination of Employment; Severance.

 

5.1 At-Will Employment. The Employee understands that this Agreement does not constitute a contract of employment and does not promise or imply that his employment will continue for any period of time. Unless otherwise agreed to under any employment or other agreement between the Employee and the Company whether executed prior to this Agreement or at any time hereafter, employment with the Company is “at will” and may be terminated either by the Employee or the Company at any time, for any or no reason, and with or without notice Either Executive or the Company may terminate Executive’s employment relationship at any time, with or without cause or advance notice, provided that in the event of a termination without Cause (as defined below), or the Executive’s resignation, either side shall provide the other with no less than ninety (90) days’ advance written notice of any such termination (the “Notice Period”). During the Notice Period, Executive shall remain an employee of the Company, and shall continue to receive Base Salary, but no other compensation. The Company may elect to have Executive not report to work for all or any portion of such Notice Period. The Company shall have the right, at its sole discretion, to accelerate Executive’s termination date to any date subsequent to receiving written notice from Executive, and thus conclude the Notice Period.

 

4

 

 

5.2 Termination Without Cause or Resignation for Good Reason.

 

a The Company may terminate Executive’s employment with the Company at any time without Cause (as defined below) and Executive may resign for Good Reason in accordance with the terms provided herein.

 

b If Executive is terminated by the Company without Cause or resigns for Good Reason, the Company shall pay Executive, as severance, (x) the equivalent of twelve (12) months of Executive’s Base Salary in effect as of the date of Executive’s employment termination, subject to standard payroll deductions and withholdings; and (y) if the termination date occurs subsequent to the conclusion of the fiscal year but prior to the payment of the Annual Bonus to which the fiscal year relates, such Annual Bonus, if any, as computed in accordance with Section 2.2 above (the “Severance Benefits”). The Severance Benefits will be paid as a continuation on the Company’s regular payroll, beginning no later than the first regularly-scheduled payroll date following the sixtieth (60th) day after Executive’s Separation from Service (as defined below), provided the Separation Agreement (as discussed in Paragraph 6) has become effective, and further provided that the Bonus component under (y), if any, shall be paid in a lump sum on the sixtieth day after Executive’s Separation from Service.

 

c For purposes of this Agreement, “Cause’’ for termination will mean: (a) commission of any (i)felony or (ii) crime involving fraud, dishonesty or moral turpitude (whether or not a felony); (b) any action by Executive involving fraud, breach of the duty of loyalty, malfeasance, willful misconduct, or negligence, (c) the failure or refusal by Executive to perform any material duties hereunder or to follow any lawful and reasonable direction of the Company; (d) intentional damage to any property of the Company (reasonable wear and tear from regular use excepted); (e) chronic neglect or absenteeism in the performance of Executive’s duties; (f) willful misconduct, gross negligence, or other material violation of Company policy or code of conduct that causes an adverse effect upon the Company; (g) breach of any written agreement with the Company (including this Employment Agreement); or (h) any action that in the reasonable belief of the Board shall or potentially shall subject the Company to material adverse publicity or effects. Prior to any termination for Cause under section (c), (e), (f), (g), or (h), the Board shall provide Executive by written notice with ten (l 0) calendar days to cure same, provided any such actions underlying Cause are determined by the Board to be curable. Any determination of Cause hereunder shall be made by the Board in its good faith discretion, which shall only be made by the Board and, to the extent deemed practicable by the Board, after providing the Executive an opportunity to respond to any determination or allegation of Cause.

 

d For purposes of this Agreement, “Good Reason’’ shall mean Executive’s resignation following the Company’s (a) material diminution of the Executive’s title or duties below that of the level of a Chief Executive Officer; (b) material and uncured breach of this Agreement; (c) material reduction in the Executive’s annual base salary as in effect on the date hereof or as the same may be increased from time to time, other than as required by exigent business circumstances; or (d) a requirement that Executive perform his job on a permanent basis more than fifty (50) miles from Farmingdale, New York; provided, that Executive shall give written notice to the Company within thirty (30) days following the occasion of any allegation of Good Reason, and the Company shall have thirty (30) days to cure same. In the event such occurrence is not cured, then Executive may terminate Executive’s employment for Good Reason hereunder within ninety (90) days from the end of the cure period. The Executive’s continued employment prior to the conclusion of the ninety (90) day period stated in the preceding sentence shall not constitute consent to, or waiver of rights with respect to, any act or failure to act by the Company constituting “Good Reason” hereunder, if not cured in the preceding thirty day period.

 

5

 

 

5.3 Termination for Any Other Reason.

 

a Upon a termination for any reason other than without Cause or for Good Reason as provided in Section 4.2(a), then upon Executive’s termination date all payments of compensation by the Company to Executive hereunder will terminate immediately (except as to amounts already earned), and Executive will not be entitled to any Severance Benefits.

 

b In the event of termination for any reason. Executive shall resign from all positions and terminate any relationships as an employee, advisor, officer or director with the Company and any of its affiliates, each effective on the date of termination.

 

6. Conditions to Receipt of Severance Benefits. In order to receive any Severance Benefits, the termination of Executive’s employment must constitute a “separation from service” (as defined under Treasury Regulation Section l.409A-l(h), without regard to any alternative definition thereunder, a “Separation from Service”), and Executive must be in compliance with the terms of this Agreement. Further, the receipt of the Severance Benefits will be conditioned on Executive signing, not revoking, and complying with a separation agreement and release of claims in a form reasonably satisfactory to the Company (the “Separation Agreement”). No Severance Benefits will be paid or provided until the Separation Agreement becomes effective.

 

7. Representations. Executive represents and warrants that the execution of this Employment Agreement, Executive’s employment by the Company, and the performance of Executive’s duties hereunder will not violate or be a breach of any agreement with a former employer, client or any other person or entity, nor does Executive know of any other reason why she would not be able to perform her duties as set forth herein. Further, Executive agree to indemnify the Company for, and hold the Company harmless from, and against, all claims, including, but not limited to, attorneys’ fees and expenses of investigation, by any such third party that such third party may now have or may hereafter come to have against the Company based upon or arising out of any noncompetition agreement, invention or secrecy agreement between Executive and such third party which was in existence as of the date of this Agreement. The Company reserves the right to rescind this offer immediately and, if applicable, terminate Executive’s employment, without any further obligation to Executive if before or during Executive’s employment the Company learns that Executive provided false information or made any misrepresentations in connection with Executive’s application for employment with the Company.

 

6

 

 

8. Section 409A. It is intended that all of the Severance Benefits and other payments payable under this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Code Section 409A provided under Treasury Regulations l.409A-l(b)(4), l.409A- l(b)(5) and l .409A-l(b)(9), and this Agreement will be construed to the greatest extent possible as consistent with those provisions, and to the extent not so exempt, this Agreement (and any definitions hereunder) will be construed in a manner that complies with Section 409A. For purposes of Code Section 409A (including, without limitation, for purposes of Treasury Regulation Section l .409A- 2(b)(2)(iii)), Executive’s right to receive any installment payments under this Agreement (whether severance payments, reimbursements or otherwise) shall be treated as a right to receive a series of separate payments and, accordingly, each installment payment hereunder shall at all times be considered a separate and distinct payment. Notwithstanding any provision to the contrary in this Agreement, if Executive is deemed by the Company at the time of Executive’s Separation from Service to be a “specified employee” for purposes of Code Section 409A(a)(2)(B)(i), and if any of the payments upon Separation from Service set forth herein and/or under any other agreement with the Company are deemed to be “deferred compensation,” then to the extent delayed commencement of any portion of such payments is required in order to avoid a prohibited distribution under Code Section 409A(a)(2)(B)(i) and the related adverse taxation under Section 409A, such payments shall not be provided to Executive prior to the earliest of (i) the expiration of the six-month period measured from the date of Executive’s Separation from Service with the Company, (ii) the date of Executive’s death or (iii) such earlier date as permitted under Section 409A without the imposition of adverse taxation. Upon the first business day following the expiration of such applicable Code Section 409A(a)(2)(B)(i) period, all payments deferred pursuant to this Paragraph shall be paid in a lump sum to Executive, and any remaining payments due shall be paid as otherwise provided herein or in the applicable agreement. No interest shall be due on any amounts so deferred.

 

9. Restrictive Covenants

 

9.1 Definitions. The following capitalized terms used in this Agreement shall have the meanings assigned to them below, which definitions shall apply to both the singular and the plural forms of such terms:

 

i Confidential Information” “Confidential Information” shall be given its broadest possible interpretation and shall mean any and all information of the Company, its affiliates, subsidiaries, and parents (each, a “Company Entity”, and collectively, “Company Entities’’), including without limitation: (i) financial and business information relating to any Company Entity, such as information with respect to costs, fees, profits, revenues, markets, mailing/client lists, strategies and plans for future business, new business, product or other development, potential acquisitions or divestitures and new marketing ideas; (ii) product and technical information relating to any Company Entity, such as software, software codes, computer models and research and development projects; (iii) customer or investor information, such as the identity of any Company Entity’s clients or investors, the names of representatives of Company Entity customer or investors responsible for entering into contracts with a Company Entity, the amounts paid by such investors or customers to any Company Entity, specific customer or investor needs and requirements, specific customer or investor risk characteristics, and specific customer or investor preferences; (iv) personnel information, such as the identity and number of any Company Entity’s other employees and officers, their salaries, bonuses, benefits, skills, qualifications, and abilities; (v) any and all information in whatever form relating to any customer or prospective customer of a Company Entity, including but not limited to its business, employees, operations, systems, assets, liabilities, finances, products, and marketing, selling and operating practices; (vi) any information related to any security system of any Company Entity or any of employees, (vii) any and all information pertaining to the business and or personal affairs of the Company’s partners, members and employees, including but not limited to their personal lives, characteristics, opinions, ideas, conduct, habits or background or their business or financial condition, affairs, dealings or operations or their personal database, personal photographs or videotapes, purchases, travel itineraries, social interactions, tax information, emails, private conversations, phone calls and correspondence; (viii) any information not included in (i) through (vii), above, which the Employee knows or should know is subject to a restriction on disclosure or which the Employee knows or should know is considered by any Company Entity’s clients or prospective clients to be confidential, sensitive, proprietary, or a trade secret or is not readily available to the public; or (ix) intellectual property, including inventions and copyrightable works. Confidential Information is not generally known or available to the general public, but has been developed, compiled, or acquired by the Company at its effort and expense. Confidential Information can be in any form, including but not limited to verbal, written, or machine readable, including electronic files. By way of example but not limitation of the foregoing, Confidential Information may be acquired by observing documents, things, people or events, by direct communication with clients or others or by overhearing conversations in person or over the telephone or otherwise. “Confidential Information” shall not include information that has become generally available to the public by the act of one who has the right to disclose such information without violating any right or privilege of the Company. Confidential Information shall also not include any information which Executive can prove by verifiable evidence was known to Executive prior to the Start Date.

 

7

 

 

ii Restricted Period” from the Start Date through the first anniversary of Executive’s Termination Date as pertains to Sections 9.3 and 9.4, and from the Start Date through the second anniversary of Executive’s Termination Date as pertains otherwise.

 

iii Person” means any individual or any corporation, partnership, joint venture, limited liability company, association or other entity or enterprise.

 

iv Restricted Business” means any person, business, entity, organization or group within a larger firm that engages in, or plans to engage in, (i) those parts of the business of the Company and any Company Entity with which you were involved during the employment or about which you received Confidential Information, or (ii) any business activity which the Company or any Company Entity was actively planning to engage in as of the Termination Date;

 

Section 8.

v Restrictive Covenants” means the covenants contained in this

 

vi Termination” means the termination of Executive’s employment with the Company, for any reason, whether with or without Cause. upon the initiative of either party.

 

vii Termination Date’’ means the date of Executive’s Termination.

 

viii Work Product’’ means all memoranda, summaries, written work product, business plans, formulas, recipes, inventions, innovations, improvements, developments, methods, designs, analyses, drawings, reports and all similar or related information (whether patentable or not) that are based upon Confidential Information and that are conceived, developed or made by Executive during his employment.

 

9.2 Restriction on Disclosure and Use of Confidential Information. Executive agrees that Executive shall not, directly or indirectly, use any Confidential Information on Executive’s own behalf or on behalf of any Person other than the Company, or reveal, divulge, or disclose any Confidential Information to any Person not expressly authorized by the Company to receive such Confidential Information. This obligation shall remain in effect for as long as the information or materials in question retain their status as Confidential Information. Executive further agrees that he shall fully cooperate with the Company in maintaining the Confidential Information to the extent permitted by law. The parties acknowledge and agree that this Agreement is not intended to, and does not, alter either the Company’s rights or Executive’s obligations under any state or federal statutory or common law regarding trade secrets and unfair trade practices. Anything herein to the contrary notwithstanding, Executive shall not be restricted from: (i) disclosing information that is required to be disclosed by law, court order or other valid and appropriate legal process; provided, however, that in the event such disclosure is required by law, Executive shall provide the Company with prompt notice of such requirement so that the Company may seek an appropriate protective order prior to any such required disclosure by Executive; or (ii) reporting possible violations of federal, state, or local law or regulation to any governmental agency or entity, or from making other disclosures that are protected under the whistleblower provisions of federal, state, or local law or regulation, and Executive shall not need the prior authorization of the Company to make any such reports or disclosures and shall not be required to notify the Company that Executive has made such reports or disclosures. Notwithstanding anything in the foregoing to the contrary, in accordance with the Defend Trade Secrets Act of 2016, Executive will not be criminally or civilly liable for disclosing a trade secret if it was disclosed: (1) to any government official or attorney in confidence directly or indirectly for the sole purpose of reporting or investigating a suspected violation of law; (2) in a complaint or other document filed in a lawsuit or other proceeding if filed under seal; or (3) to an attorney or used in a court proceeding in a retaliation lawsuit if any document containing a trade secret is filed under seal and is not disclosed except pursuant to court order.

 

9.3 Non-Competition. The Executive acknowledges and agrees that solely by reason of employment by the Company, the Executive has and will come into contact with a significant number of the Company’s customers and prospective customers and have access to Confidential Information (as defined herein) and trade secrets relating thereto, including those regarding the Company’s clients, prospective clients, proprietary business models and strategies, and related information. Consequently, the Employee covenants and agrees that during the Restricted Period, Executive shall not directly or indirectly, an individual proprietor, partner, stock-holder, officer, employee, director, joint venturer, investor, lender, or in any other capacity whatsoever (other than as the holder of not more than three percent (3%) of the total outstanding stock of a publicly held company), engage in the Restricted Business.

 

8

 

 

9.4 Non-Solicitation. Executive agrees that, during the Restricted Period, he shall not, directly or indirectly, in his own capacity or through any other entity or person: (i) solicit, persuade or induce any investor of the Company to terminate, reduce, disrupt or refrain from renewing or extending its contractual or other relationship with the Company in regard to the purchase of products or services, procured, performed, manufactured, marketed, or sold, by the Company; (ii) in any way interfere with the relationship between any such investor, client, supplier, licensee, licensor, franchisee or business relation of the Company and/or any of its affiliates; (iii) induce or attempt to induce any employee of the Company or any of its affiliates to leave the employ of the Company and/or any of its affiliates, or in any way interfere with the relationship between the Company and/or any of its affiliates on the one hand and any employee thereof on the other hand; or (iv) solicit to hire (other than through general advertisements for employment not directed at employees of the Company or any of its affiliates) or hire any person who was an employee of any of the Company or any of its affiliates at any time during the one (1) year preceding such solicitation.

 

9.5 Non-Disparagement. Executive agrees that, at any time hereinafter, he will not do or say anything, including but not limited to communicating on the internet (including but not limited to any posting or reference on any social networking site), or via e-mail, telephone, face-to face communication, or otherwise, that (i) criticizes or disparages the Company or its management, practices, policies, products or services; (ii) disrupts or impairs the normal, ongoing business operations of Company, or any member of the Company Group; or (iii) harms the business reputation of Company or the Company Group with its employees, customers, suppliers, contractors or the public. Executive will not discuss any information (whether confidential or not) about the Company with any reporter, author, producer, or similar person or entity, or take any other action seeking to publicize or disclose any such information in any way likely to result in such information being made available to the general public in any form, including books, articles or writings of any kind, as well as film, videotape, audiotape or any other medium or as commonly provided on a resume. Executive acknowledges and agree that these prohibitions extend to statements, written or verbal, made to anyone and includes statements made via social media including on blogs or social networking sites, including but not limited to Facebook, LinkedIn, or Twitter. Neither the Board nor the Company or any of its affiliates shall authorize any disparaging comments about Executive. Notwithstanding the foregoing, nothing in this paragraph shall prevent either Executive, the Board or the Company or any of its affiliates from making any truthful statement to the extent necessary with respect to any litigation, arbitration, or mediation involving this Agreement, including, but not limited to, enforcement of this Agreement or as required by law or by any court, arbitrator, mediator, or administrative or legislative body with actual or apparent jurisdiction to order such person to disclose or make accessible such information.

 

9.6 Return of Materials. Executive agrees that he will not retain or destroy (except as set forth below), and will immediately return to the Company on or, if specifically requested, prior to the Termination Date, or at any other time the Company requests such return, any and all Company property, including Confidential Information and all other documents, materials, information, and property, including but not limited to memoranda, letters, notes, plans, reports, analyses, recaps, jump drives, disks, tapes, journals, notebooks, and any Company-provided computer, cell phone, Blackberry, beeper, keys, key fob, security card, phone card, credit cards, computer user name and password, and/or voicemail code, all other files and documents relating to the Company and its business (regardless of form, but specifically including all electronic files and data of the Company). Executive will not make, distribute, or retain copies of any such information or property. Executive agrees that the ownership and right of control of all programs, databases, electronic files, reports, records and supporting documents prepared by, for or on behalf of Executive in connection with the performance of Executive’s duties during his employment are vested exclusively in the Company and remain the exclusive property of the Company.

 

9

 

 

9.7 Inventions. Executive acknowledges and agrees that any and all Work Product, products, improvements, and inventions or creations conceived or made by Executive during the period of Executive’s employment with the Company relating to the activities or business of the Company or the Company Group are the sole and exclusive property of the Company or its nominee. Executive shall promptly disclose any Work Product to the Company and perform all acts and things and sign whatever documents and agreements are necessary to confirm and vest the entire right, title and interest in such Work Product in the Company, including copyright assignments, patent applications and other documents and papers. Any assignment of Work Product includes all rights of attribution, paternity, integrity, modification, disclosure and withdrawal, and any other rights throughout the world that may be known as or referred to as “moral rights,” “artist’s rights,” “droit moral” or the like (collectively, “Moral Rights”). To the extent that Moral Rights cannot be assigned under applicable law, Executive hereby waives and agrees not to enforce any and all Moral Rights, including, without limitation, any limitation on subsequent modification, to the extent permitted under applicable law. Executive agrees to assist the Company, or its designee, at its expense, in every proper way to secure the Company’s, or its designee’s, rights in the Company Inventions and any copyrights, patents, trademarks, mask work rights, Moral Rights, or other intellectual property rights relating thereto in any and all countries, including the disclosure to the Company or its designee of all pertinent information and data with respect thereto, the execution of all applications, specifications, oaths, assignments, recordations, and all other instruments which the Company or its designee shall deem necessary in order to apply for, obtain, maintain and transfer such rights, or if not transferable, waive and agree never to assert such rights, and in order to assign and convey to the Company or its designee, and any successors, assigns and nominees the sole and exclusive right, title and interest in and to such Company Inventions, and any copyrights, patents, mask work rights or other intellectual property rights relating thereto. Executive hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as Executive’s agent and attorney-in-fact, to act for and in Executive’s behalf and stead to execute and file any such instruments and papers and to do all other lawfully permitted acts to further the application for, prosecution, issuance, maintenance or transfer of patent, copyright, mask work and other registrations related to such Work Product. These obligations shall be binding upon Executive and Executive’s heirs, assigns, executors, administrators, agents or other legal representatives. Executive may not use, disclose to third parties or otherwise retain any such works or inventions, without the prior written permission of the Company.

 

9.8 Cooperation. The Executive shall cooperate with the Company and its counsel in connection with any litigation or regulatory or self-regulatory inquiry, investigation or proceeding relating to activities of Executive, or by activities of others of which the Executive may have knowledge, and this obligation shall survive the termination of this Agreement. The Company shall reimburse the Executive for reasonable out-of-pocket travel and other reasonable incidental expenses (other than legal expenses unless such legal expenses are requested by the Executive as a result of divergent interests between Executive and the Company, and approved by the Board in writing) incurred as a result of the Executive’s cooperation pursuant to the immediately preceding sentence.

 

10

 

 

9.9 Exceptions. Nothing in this Agreement shall limit the rights of any government agency or any party’s right of access to, participation or cooperation with any government agency. Notwithstanding anything to the foregoing, nothing herein, or in any other agreement or policy, shall limit Executive’s right under applicable law to file a charge or complaint with the U.S. Equal Employment Opportunity Commission, the National Labor Relations Board, the Occupational Safety and Health Administration, the Securities and Exchange Commission, or any other federal, state or local governmental agency or commission (’’Government Agencies”). Executive further understands that this Agreement does not limit his ability to communicate with any Government Agencies or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including providing documents or other information, without notice to the Company. This Agreement does not limit Executive’s right to receive an award for information provided to any Government Agencies.

 

9.10 Enforcement of Restrictive Covenants.

 

i Rights and Remedies Upon Breach. The parties specifically acknowledge and agree that the remedy at law for any breach of the Restrictive Covenants will be inadequate, and that in the event Executive breaches, or threatens to breach, any of the Restrictive Covenants, the Company shall have the right and remedy, without the necessity of proving actual damage or posting any bond, to enjoin, preliminarily and permanently, Executive from violating or threatening to violate the Restrictive Covenants and to have the Restrictive Covenants specifically enforced by any court of competent jurisdiction, it being agreed that any breach or threatened breach of the Restrictive Covenants would cause irreparable injury to the Company and that money damages would not provide an adequate remedy to the Company.

 

ii Severability and Modification of Covenants. Executive acknowledges and agrees that each of the Restrictive Covenants is reasonable and valid in time and scope and in all other respects. The parties agree that it is their intention that the Restrictive Covenants be enforced in accordance with their terms to the maximum extent permitted by law. Each of the Restrictive Covenants shall be considered and construed as a separate and independent covenant. Should any part or provision of any of the Restrictive Covenants be held invalid, void, or unenforceable, such invalidity, voidness, or unenforceability shall not render invalid, void, or unenforceable any other part or provision of this Agreement or such Restrictive Covenant. If any of the provisions of the Restrictive Covenants should ever be held by a court of competent jurisdiction to exceed the scope permitted by the applicable law, such provision or provisions shall be automatically modified to such lesser scope as such court may deem just and proper for the reasonable protection of the Company’s legitimate business interests and may be enforced by the Company to that extent in the manner described above and all other provisions of this Agreement shall be valid and enforceable.

 

10. Third Party Confidential Information. In Executive’s work for the Company, Executive will be expected to not, and shall not to use or disclose any confidential information, including trade secrets, of any former employer or other person to whom Executive has an obligation of confidentiality. Rather, Executive will be expected to use only that information which is generally known and used by persons with training and experience comparable to Executive’s own, which is common knowledge in the industry or otherwise legally in the public domain, or which is otherwise provided or developed by the Company. Executive agrees not to bring onto Company premises any unpublished documents or property belonging to any former employer or other person to whom Executive has an obligation of confidentiality.

 

11

 

 

11. Governing Law; Dispute Resolution. The interpretation and application of this Employment shall be governed by the laws of the State of New York without regard to principles of conflict of laws, other than laws which violate a fundamental public policy of the state of employ, in which case such state’s laws shall govern with regard to such policies. Except for claims requesting injunctive relief, any dispute or claim arising out of, in connection with, or relating to this Agreement (including without limitation its subject matter, interpretation, or formation) or to Executive’s employment or relationship with the Company shall be resolved by binding arbitration to be held in or around Farmingdale, New York, before three (3) arbitrators selected by the American Arbitration Association, conducted in accordance with the then-prevailing Employment Arbitration Rules and Mediation Procedures of the American Arbitration Association. A copy of these rules can be accessed through the American Arbitration Association’s website (www.adr.org). The arbitrators’ decision will be final and binding in accordance with the Federal Arbitration Act and may be enforced in any court of competent jurisdiction. The arbitrators will not have the right to modify or change any of the terms of this Employment Agreement. The arbitrators, and not any court, shall have exclusive authority to resolve any dispute relating to the interpretation, applicability, enforceability or formation of this Employment Agreement including any claim that all or any part of this Agreement is void or voidable. The parties agree that the arbitrators may provide all appropriate remedies at law and equity and will have the power to summarily adjudicate claims and/or enter summary judgment in appropriate cases. In any arbitration proceeding conducted pursuant to this paragraph, the parties shall have the right to discovery, to call witnesses, and to cross-examine the other party’s witnesses. The arbitrator shall render a final decision in writing, setting forth the reasons for the arbitration award. Both parties are bound by this agreement to arbitrate, but it does not include disputes, controversies or differences which may not by law be arbitrated. The parties agree that the arbitration proceedings described in this Section 10 are to be treated as confidential, and that the parties will act to protect the confidentiality of the documents, facts, and proceedings related to the arbitration. THE PARTIES WAIVE THEIR RIGHT TO HAVE ANY SUCH DISPUTE, CLAIM OR CONTROVERSY DECIDED BY A JUDGE OR JURY IN A COURT. THE PARTIES ALSO AGREE THAT EACH MAY BRING CLAIMS AGAINST THE OTHER ONLY IN THEIR INDIVIDUAL CAPACITIES, AND NOT AS A PLAINTIFF OR CLASS MEMBER IN ANY PURPORTED CLASS OR COLLECTIVE PROCEEDING. THE PARTIES ALSO AGREE THAT EACH MAY NOT BRING CLAIMS AGAINST THE OTHER IN ANY PURPORTED REPRESENTATIVE ACTION, EXCEPT TO THE EXTENT THIS STATEMENT IS UNENFORCEABLE UNDER THE LAW.

 

12. General Provisions.

 

12.1 Notices. Any notices provided must be in writing and will be deemed effective upon the earlier of personal delivery, email, or the next day after sending by overnight carrier, to the Company at its primary office location and to Executive at the address as listed on the Company payroll.

 

12.2 Severability. Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced in such jurisdiction to the extent possible in keeping with the intent of the parties.

 

12.3 Waiver. Any waiver of any breach of any provisions of this Agreement must be in writing to be effective, and it shall not thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement.

 

12

 

 

12.4 Complete Agreement. This Agreement constitutes the entire agreement between Executive and the Company with regard to this subject matter and is the complete, final, and exclusive embodiment of the Parties’ agreement with regard to this subject matter. This Agreement is entered into without reliance on any promise or representation, written or oral, other than those expressly contained herein, and it supersedes any other such promises, warranties or representations. It is entered into without reliance on any promise or representation other than those expressly contained herein, and it cannot be modified or amended except in a writing signed by a duly authorized officer of the Company.

 

12.5 Counterparts. This Agreement may be executed in separate counterparts, any one of which need not contain signatures of more than one party, but all of which taken together will constitute one and the same Agreement.

 

12.6 Headings. The headings of the paragraphs hereof are inserted for convenience only and shall not be deemed to constitute a part hereof nor to affect the meaning thereof.

 

12.7 Successors and Assigns. This Agreement is intended to bind and inure to the benefit of and be enforceable by Executive and the Company, and their respective successors, assigns, heirs, executors and administrators. The Company may freely assign this Agreement, without Executive’s prior written consent. Executive may not assign any of his duties hereunder and he may not assign any of her rights hereunder without the written consent of the Company. The Company will require any successor (whether direct or indirect, by purchase, merger, consolidation, assign or otherwise) to all or substantially all of the business and/or assets of the Company to assume expressly and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place. As used in this Agreement, “Company” shall mean the Company as hereinbefore defined and any successor to its business and/or assets as aforesaid.

 

12.8 Background Check and Ability to Work. This offer of employment is contingent upon verification of Executive’s identity and authorization to legally work in the United States, a background and reference check, and all other Company practices and procedures as reasonably requested by the Company.

 

12.9 Tax Withholding. All payments and awards contemplated or made pursuant to this Agreement will be subject to withholdings of applicable taxes in compliance with all relevant laws and regulations of all appropriate government authorities. Executive acknowledges and agrees that the Company has neither made any assurances nor any guarantees concerning the tax treatment of any payments or awards contemplated by or made pursuant to this Agreement. Executive has had the opportunity to retain a tax and financial advisor and fully understands the tax and economic consequences of all payments and awards made pursuant to the Agreement.

 

***

 

13

 

 

You acknowledge and agree that you have read and understand this Employment agreement and you voluntarily agree to the terms and conditions contained herein.

 

We look Forward to you continuing your employment with the Company. If you accept this second amended offer of employment, please sign and return to me this Employment Agreement attached by no later than november 2, 2022 or this offer shall expire.

 

In Witness Whereof, the Parties have executed this Agreement on the day and year first written above.

 

  ENZO BIOCHEM INC.
   
  By: /s/ Ian B. Walters
    Ian B. Walters, MD compensation chair
     
  Executive
   
  /s/ Hamid Erfanian

 

 

14

 

EX-101.SCH 4 enz-20221020.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 enz-20221020_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 enz-20221020_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover
Oct. 20, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 20, 2022
Entity File Number 001-09974
Entity Registrant Name Enzo Biochem, Inc.
Entity Central Index Key 0000316253
Entity Tax Identification Number 13-2866202
Entity Incorporation, State or Country Code NY
Entity Address, Address Line One 81 Executive Blvd
Entity Address, Address Line Two Suite 3
Entity Address, City or Town Farmingdale
Entity Address, State or Province NY
Entity Address, Postal Zip Code 11735
City Area Code (212)
Local Phone Number 583-0100
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.01 par value
Trading Symbol ENZ
Security Exchange Name NYSE
Entity Emerging Growth Company false
XML 8 ea167979-8k_enzobio_htm.xml IDEA: XBRL DOCUMENT 0000316253 2022-10-20 2022-10-20 iso4217:USD shares iso4217:USD shares 0000316253 false 8-K 2022-10-20 Enzo Biochem, Inc. NY 001-09974 13-2866202 81 Executive Blvd Suite 3 Farmingdale NY 11735 (212) 583-0100 false false false false Common Stock, $0.01 par value ENZ NYSE false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://enzo.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea167979-8k_enzobio.htm ea167979ex10-1_enzobio.htm ea167979ex10-2_enzobio.htm enz-20221020.xsd enz-20221020_lab.xml enz-20221020_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ea167979-8k_enzobio.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "ea167979-8k_enzobio.htm" ] }, "labelLink": { "local": [ "enz-20221020_lab.xml" ] }, "presentationLink": { "local": [ "enz-20221020_pre.xml" ] }, "schema": { "local": [ "enz-20221020.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ENZ", "nsuri": "http://enzo.com/20221020", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "ea167979-8k_enzobio.htm", "contextRef": "From2022-10-20to2022-10-20", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://enzo.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "ea167979-8k_enzobio.htm", "contextRef": "From2022-10-20to2022-10-20", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 15 0001213900-22-069123-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-22-069123-xbrl.zip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